ReviewBreast cancer (Dove Medical Press)2026
Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.
Review in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trial watch: antibody-drug conjugates in cancer therapy.Oncoimmunology · 2026Review
- Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.Translational oncology · 2026Article
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive nature and lack of ER, PR and HER2 expression. Recent advances, however, are reshaping its treatment landscape, particularly with antibody-drug conjugates (ADCs) and immunotherapies. ADCs such as sacituzumab govitecan and datopotamab deruxtecan have demonstrated superior efficacy over standard chemotherapy in metastatic TNBC. Furthermore, combining these ADCs with immune checkpoint inhibitors is emerging as a powerful strategy to enhance antitumor activity, as evidenced by encouraging results from trials like MORPHEUS-panBC and BEGONIA. While most evidence currently centers on metastatic disease, these novel combinations are also being rapidly evaluated in neoadjuvant and adjuvant settings. Given this rapid progress, this article aims to summarize recent advances in ADCs and immunotherapy combinations for TNBC, discuss their synergistic mechanisms, and provide insights for future personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.